Table 1. Demographic information for included studies with SALL4 expression.

Reference	Country	Cancer type	No.	Mean age (y)	Male/Female	TNM stage	Median follow-up (m)	SALL4 (−/+)	Subcellular localization	NOS score
Deng et al 2015 [9]	China	Liver cancer	175	55.0 ± 13.6	93/82	NA	NA	73/102	Nucleus	7
Han et al 2014 [10]	China	Liver cancer	38	52.7 ± 12.5	35/3	I–IV	NA	20/18	Nucleus	6
He et al 2012 [11]	China	Ovarian cancer	90	61.8	All female	I–IV	88 (2–160)	62/28	Nucleus	7
Li et al 2015 [12]	USA	Endometrial cancer	113	57.3 ± 10.6	All female	I–IV	50 (0–143)	59/54	Nucleus	8
Liu et al 2014 [13]	USA	Liver cancer	236	62.0	165/71	NA	NA	233/3	Nucleus	7
Oikawa et al 2013 [14]	Japan	Liver cancer	139	57.0	102/37	I–IV	23	29/110	Nucleus	8
Osada et al 2014 [15]	Japan	Gastric cancer	92	63.4	46/46	I–IV	NA	68/24	Nucleus	7
Park et al 2015 [16]	Korea	Liver cancer	190	58.1 ± 11.8	151/39	I–IV	52 (0–133)	151/39	Nucleus	8
Shibahara et al 2014 [17]	Japan	Liver cancer	337	64.6	263/74	NA	0–48	290/47	Nucleus	7
Tanaka et al 2015 [18]	Japan	Liver cancer	90	NA	71/19	I–IV	NA	82/8	Nucleus	7
Yong et al 2013 [19]	Singapore	Liver cancer-SG	79	56.2	64/15	I–IV	98 (0–255)	34/45	Nucleus	7
		Liver cancer-HK	228	55.0	179/49	I–IV	75 (0–134)	114/114	Nucleus	7
Yue et al 2015 [20]	China	Breast cancer	160	51.0	All female	I–III	0–144	57/103	Nucleus	8
Zeng et al 2014 [21]	Japan	Liver cancer	144	62.7 ± 1.9	110/34	I–IV	NA	101/43	Nucleus	7

No.: number; y: year; m: month; NA: not available; NOS: Newcastle-Ottawa Scale; SG: Singapore Cohort; HK: Hong Kong Cohort.